Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Onyx Pharmaceuticals
Sponsor:
Information provided by (Responsible Party):
Onyx Pharmaceuticals ( Onyx Therapeutics, Inc. )
ClinicalTrials.gov Identifier:
NCT01416428
First received: August 11, 2011
Last updated: September 24, 2014
Last verified: September 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2016
  Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)